ArticleJAMA oncology2022

Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.

Abdulhadi Jfri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.